BidaskClub upgraded shares of Beigene (NASDAQ:BGNE) from a hold rating to a buy rating in a research report released on Friday, January 5th.
BGNE has been the topic of several other research reports. Zacks Investment Research upgraded shares of Beigene from a hold rating to a buy rating and set a $115.00 price objective on the stock in a report on Tuesday, October 3rd. Maxim Group reaffirmed a buy rating and issued a $77.00 target price on shares of Beigene in a research note on Monday, September 11th. Cowen reaffirmed a buy rating on shares of Beigene in a research note on Monday, December 11th. Morgan Stanley reaffirmed an overweight rating and issued a $95.00 target price (up from $87.00) on shares of Beigene in a research note on Friday, October 6th. Finally, Robert W. Baird reissued a neutral rating and set a $83.00 price objective (up from $58.00) on shares of Beigene in a research report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company has an average rating of Hold and a consensus price target of $96.67.
Beigene (BGNE) traded up $1.44 on Friday, hitting $103.28. 140,600 shares of the company were exchanged, compared to its average volume of 180,956. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33. The stock has a market capitalization of $4,695.83, a P/E ratio of -79.45 and a beta of -1.03. Beigene has a one year low of $31.70 and a one year high of $118.95.
In other Beigene news, CEO John Oyler sold 150,957 shares of Beigene stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total value of $12,152,038.50. Following the completion of the transaction, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at approximately $39,597,225.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CMO Jane Huang sold 600 shares of Beigene stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $85.00, for a total value of $51,000.00. Following the completion of the transaction, the chief marketing officer now directly owns 264,900 shares of the company’s stock, valued at $22,516,500. The disclosure for this sale can be found here. Insiders have sold a total of 483,482 shares of company stock valued at $42,139,474 over the last three months. Corporate insiders own 19.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BGNE. First Trust Advisors LP grew its position in Beigene by 2.2% in the 2nd quarter. First Trust Advisors LP now owns 48,860 shares of the company’s stock valued at $2,199,000 after acquiring an additional 1,029 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Beigene in the second quarter valued at about $111,000. Alliancebernstein L.P. acquired a new stake in shares of Beigene in the second quarter valued at about $7,373,000. Baillie Gifford & Co. grew its stake in shares of Beigene by 5.0% in the second quarter. Baillie Gifford & Co. now owns 74,424 shares of the company’s stock valued at $3,349,000 after buying an additional 3,559 shares in the last quarter. Finally, Profund Advisors LLC acquired a new stake in shares of Beigene in the second quarter valued at about $248,000. 55.32% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/beigene-bgne-raised-to-buy-at-bidaskclub/1818425.html.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.